|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
ES2874149T3
(es)
|
2006-05-11 |
2021-11-04 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen PCSK9
|
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
EA036772B1
(ru)
|
2008-10-20 |
2020-12-18 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
EP2373382B1
(en)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
JP5889783B2
(ja)
*
|
2009-05-05 |
2016-03-22 |
テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ |
免疫細胞へオリゴヌクレオチドを送達する方法
|
|
MX342785B
(es)
|
2009-06-10 |
2016-10-12 |
Alnylam Pharmaceuticals Inc |
Formulacion mejorada de lipido.
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
US8236943B2
(en)
|
2009-07-01 |
2012-08-07 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
EP2467357B1
(en)
|
2009-08-20 |
2016-03-30 |
Sirna Therapeutics, Inc. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
CA2816925C
(en)
|
2009-11-04 |
2023-01-10 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
|
HUE042177T2
(hu)
|
2009-12-01 |
2019-06-28 |
Translate Bio Inc |
Szteroidszármazék mRNS szállítására humán genetikai betegségekben
|
|
WO2011071860A2
(en)
|
2009-12-07 |
2011-06-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions for nucleic acid delivery
|
|
CA2784568A1
(en)
*
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Lipid particles for delivery of nucleic acids
|
|
WO2011076807A2
(en)
*
|
2009-12-23 |
2011-06-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
EP2558074B1
(en)
|
2010-04-08 |
2018-06-06 |
The Trustees of Princeton University |
Preparation of lipid nanoparticles
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
JP5902616B2
(ja)
*
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
US20130129811A1
(en)
*
|
2010-04-28 |
2013-05-23 |
Takeshi Kuboyama |
Cationic lipid
|
|
US9254327B2
(en)
*
|
2010-05-10 |
2016-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
WO2011141703A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
SG186085A1
(en)
|
2010-06-03 |
2013-01-30 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
HUE026646T2
(en)
|
2010-07-06 |
2016-07-28 |
Glaxosmithkline Biologicals Sa |
Preferred liposomes containing lipids of PKA value for delivery of RNA
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
HUE047796T2
(hu)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
RNS bevitele több immunútvonal bekapcsolására
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012016184A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
PT3970742T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
CN103221549A
(zh)
|
2010-08-31 |
2013-07-24 |
默沙东公司 |
用于递送寡核苷酸的新型简单化学实体和方法
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
ES2888231T3
(es)
|
2010-09-20 |
2022-01-03 |
Sirna Therapeutics Inc |
Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
|
|
EP2621480B1
(en)
|
2010-09-30 |
2018-08-15 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
JP2013544504A
(ja)
|
2010-10-11 |
2013-12-19 |
ノバルティス アーゲー |
抗原送達プラットフォーム
|
|
JP2013545727A
(ja)
|
2010-10-21 |
2013-12-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
EP2635265B1
(en)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
US20120136073A1
(en)
*
|
2010-11-15 |
2012-05-31 |
Life Technologies Corporation |
Amine-Containing Transfection Reagents and methods for making and using same
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
IT1404011B1
(it)
*
|
2010-12-03 |
2013-11-08 |
Uni Degli Studi Magna Graecia Di Catanzaro |
Nanovettore coniugato con tsh per il trattamento del cancro della tiroide
|
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
EA039892B1
(ru)
*
|
2011-05-23 |
2022-03-24 |
Элнилэм Фармасьютикалз, Инк. |
Биоразлагаемые липиды для доставки активных агентов
|
|
PL3586861T3
(pl)
|
2011-06-08 |
2022-05-23 |
Translate Bio, Inc. |
Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
|
|
EP3354644A1
(en)
|
2011-06-08 |
2018-08-01 |
Translate Bio, Inc. |
Cleavable lipids
|
|
CN103649103A
(zh)
|
2011-06-21 |
2014-03-19 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
CA2845845A1
(en)
*
|
2011-08-31 |
2013-03-07 |
Mallinckrodt Llc |
Nanoparticle peg modification with h-phosphonates
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
JP6294229B2
(ja)
*
|
2011-10-18 |
2018-03-14 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アミン陽イオン性脂質およびその使用
|
|
EP2594575A1
(en)
*
|
2011-11-15 |
2013-05-22 |
Université de Strasbourg |
Mannosylated compounds useful for the prevention and the treatment of infectious diseases
|
|
JP6093710B2
(ja)
|
2011-11-18 |
2017-03-08 |
日油株式会社 |
細胞内動態を改善したカチオン性脂質
|
|
HUE048622T2
(hu)
|
2011-11-18 |
2020-08-28 |
Alnylam Pharmaceuticals Inc |
RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
EP2788006B1
(en)
|
2011-12-07 |
2026-01-07 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
EP2788316B1
(en)
|
2011-12-07 |
2019-04-24 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
JP2015502365A
(ja)
|
2011-12-12 |
2015-01-22 |
オンコイミューニン，インコーポレイティド |
オリゴヌクレオチドのイン−ビボ送達
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
SG11201405157PA
(en)
*
|
2012-02-24 |
2014-10-30 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
US8546617B1
(en)
|
2012-03-23 |
2013-10-01 |
Empire Technology Development Llc |
Dioxaborinanes and uses thereof
|
|
HK1206644A1
(en)
|
2012-03-29 |
2016-01-15 |
Shire Human Genetic Therapies, Inc. |
Lipid-derived neutral nanoparticles
|
|
ES2762873T3
(es)
*
|
2012-03-29 |
2020-05-26 |
Translate Bio Inc |
Lípidos catiónicos ionizables
|
|
CA2868391A1
(en)
*
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
AU2013243948A1
(en)
*
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
AU2013249548A1
(en)
|
2012-04-19 |
2014-11-06 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
US10245229B2
(en)
|
2012-06-08 |
2019-04-02 |
Translate Bio, Inc. |
Pulmonary delivery of mRNA to non-lung target cells
|
|
TW201726600A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
|
WO2014008334A1
(en)
|
2012-07-06 |
2014-01-09 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
US9120938B2
(en)
|
2012-07-31 |
2015-09-01 |
Empire Technology Development Llc |
Polymerizable organoboron alkyd resin anti fouling coatings
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US10125369B2
(en)
|
2012-12-05 |
2018-11-13 |
Alnylam Pharmaceuticals, Inc. |
PCSK9 iRNA compositions and methods of use thereof
|
|
EP3608308B1
(en)
*
|
2013-03-08 |
2021-07-21 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
DK2970456T3
(da)
|
2013-03-14 |
2021-07-05 |
Translate Bio Inc |
Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
|
|
PL3467108T3
(pl)
|
2013-03-14 |
2024-09-30 |
Translate Bio, Inc. |
Sposoby oczyszczania informacyjnego rna
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
KR20210122917A
(ko)
|
2013-03-14 |
2021-10-12 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
CA2906732C
(en)
|
2013-03-15 |
2023-08-08 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US10130649B2
(en)
|
2013-03-15 |
2018-11-20 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
TW201534578A
(zh)
*
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
AU2014340149B2
(en)
|
2013-10-22 |
2020-12-24 |
Shire Human Genetic Therapies, Inc. |
CNS delivery of mRNA and uses thereof
|
|
MX2016005238A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
|
|
ES2707966T3
(es)
|
2013-10-22 |
2019-04-08 |
Translate Bio Inc |
Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
|
|
EA034103B1
(ru)
|
2013-10-22 |
2019-12-27 |
Транслейт Био, Инк. |
СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
|
KR101647178B1
(ko)
*
|
2013-11-28 |
2016-08-23 |
충남대학교산학협력단 |
효소 절단성 링커 또는 올리고 라이신을 포함하는 폴리에틸렌글리콜-리피드를 이용한 안정화된 플라스미드-지질 입자
|
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
PT3134506T
(pt)
|
2014-04-25 |
2019-10-31 |
Translate Bio Inc |
Métodos de purificação de rna mensageiro
|
|
DK3137476T3
(da)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
Linker-modificerede oligomerforbindelser
|
|
EP3862362A3
(en)
|
2014-05-01 |
2021-10-27 |
Ionis Pharmaceuticals, Inc. |
Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
|
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
|
PT3137605T
(pt)
|
2014-05-01 |
2020-12-18 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão de angiopoietina de tipo 3
|
|
CN110903337A
(zh)
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
CN105085292B
(zh)
*
|
2014-05-23 |
2017-12-15 |
上海交通大学 |
3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
|
|
CN105085295A
(zh)
*
|
2014-05-23 |
2015-11-25 |
上海交通大学 |
氨甲环酸的两亲性衍生物及其用途
|
|
CN105085437B
(zh)
*
|
2014-05-23 |
2018-07-03 |
上海交通大学 |
3-(1-叔丁氧羰酰哌嗪-4-yl)丙酸的两亲性衍生物及其用途
|
|
JP6557722B2
(ja)
|
2014-05-30 |
2019-08-07 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
核酸の送達のための生分解性脂質
|
|
EP3160959B1
(en)
|
2014-06-24 |
2023-08-30 |
Translate Bio, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
CA2959358C
(en)
*
|
2014-06-30 |
2022-07-26 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
BR112016030852A2
(pt)
|
2014-07-02 |
2018-01-16 |
Shire Human Genetic Therapies |
encapsulação de rna mensageiro
|
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
WO2016021683A1
(ja)
|
2014-08-07 |
2016-02-11 |
武田薬品工業株式会社 |
カチオン性脂質
|
|
DK3185957T3
(da)
|
2014-08-29 |
2022-08-29 |
Alnylam Pharmaceuticals Inc |
Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
TWI710633B
(zh)
|
2014-11-10 |
2020-11-21 |
美商阿尼拉製藥公司 |
Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
|
|
HK1244843A1
(zh)
|
2014-11-17 |
2018-08-17 |
Alnylam Pharmaceuticals, Inc. |
载脂蛋白c3(apoc3)irna组合物及其使用方法
|
|
WO2016090262A1
(en)
|
2014-12-05 |
2016-06-09 |
Shire Human Genetic Therapies, Inc. |
Messenger rna therapy for treatment of articular disease
|
|
US10172924B2
(en)
|
2015-03-19 |
2019-01-08 |
Translate Bio, Inc. |
MRNA therapy for pompe disease
|
|
AU2016237148A1
(en)
|
2015-03-24 |
2017-11-23 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
CN104892473B
(zh)
*
|
2015-04-16 |
2017-01-11 |
武汉工程大学 |
一种4-巯基-1-丁醇的合成工艺
|
|
SG11201707663SA
(en)
|
2015-04-17 |
2017-11-29 |
Curevac Ag |
Lyophilization of rna
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
EP3297682B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
LT3313829T
(lt)
|
2015-06-29 |
2024-08-12 |
Acuitas Therapeutics Inc. |
Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
|
|
CA2991894A1
(en)
|
2015-07-10 |
2017-01-19 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
JP2018150239A
(ja)
*
|
2015-07-15 |
2018-09-27 |
協和発酵キリン株式会社 |
β２ＧＰＩ遺伝子発現抑制ＲＮＡｉ医薬組成物
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
US20180214575A1
(en)
*
|
2015-07-24 |
2018-08-02 |
Fibralign Corporation |
Composition For Targeted Delivery Of Nucleic Acid-Based Therapeutics
|
|
CN108138182B
(zh)
|
2015-07-31 |
2022-08-19 |
阿尔尼拉姆医药品有限公司 |
甲状腺素运载蛋白(TTR)iRNA组合物及其治疗或预防TTR相关疾病的使用方法
|
|
WO2017031232A1
(en)
*
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
US10544181B2
(en)
*
|
2015-08-25 |
2020-01-28 |
Kyushu University |
Sugar derivative gelators
|
|
KR20250145703A
(ko)
|
2015-09-02 |
2025-10-13 |
알닐람 파마슈티칼스 인코포레이티드 |
프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
|
|
EP4286012A3
(en)
|
2015-09-17 |
2024-05-29 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
PL3350333T3
(pl)
|
2015-09-17 |
2022-03-07 |
Modernatx, Inc. |
Polinukleotydy zawierające region stabilizujący ogon
|
|
JP6877414B2
(ja)
|
2015-09-24 |
2021-05-26 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｋｒａｓ発現のモジュレーター
|
|
US10940201B2
(en)
*
|
2015-09-30 |
2021-03-09 |
Shionogi & Co., Ltd. |
Nucleic acid derivative having immunostimulatory activity
|
|
KR102230325B1
(ko)
*
|
2015-09-30 |
2021-03-19 |
시오노기 앤드 컴파니, 리미티드 |
면역 부활 활성을 갖는 핵산 유도체
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
CN114686548A
(zh)
|
2015-10-14 |
2022-07-01 |
川斯勒佰尔公司 |
用于增强生产的rna相关酶的修饰
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
CA3002912A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
MX2018004917A
(es)
*
|
2015-10-22 |
2019-04-01 |
Modernatx Inc |
Vacuna de virus sincitial respiratorio.
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US20190046555A1
(en)
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
|
AU2016349625B2
(en)
|
2015-11-06 |
2022-07-07 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
|
HUE057877T2
(hu)
|
2015-12-22 |
2022-06-28 |
Modernatx Inc |
Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
|
|
US10525138B2
(en)
|
2015-12-25 |
2020-01-07 |
Kyowa Hakko Kirin Co., Ltd. |
Compound as cationic lipid
|
|
KR102515329B1
(ko)
|
2016-03-07 |
2023-03-29 |
애로우헤드 파마슈티컬스 인코포레이티드 |
치료용 화합물을 위한 표적화 리간드
|
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
WO2017177169A1
(en)
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
WO2017186711A1
(en)
|
2016-04-25 |
2017-11-02 |
Invivogen |
Novel complexes of immunostimulatory compounds, and uses thereof
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
KR20230074598A
(ko)
|
2016-05-18 |
2023-05-30 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
CN106046118A
(zh)
*
|
2016-05-26 |
2016-10-26 |
首都医科大学 |
含S‑β‑咔啉‑3‑酰基‑RGDV的siRNA递送系统的制备及其在SURVIVIN基因沉默上的应用
|
|
CA3027312A1
(en)
|
2016-06-13 |
2017-12-21 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
|
US10927383B2
(en)
|
2016-06-30 |
2021-02-23 |
Ethris Gmbh |
Cas9 mRNAs
|
|
ES2935658T3
(es)
|
2016-07-15 |
2023-03-09 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la modulación de SMN2
|
|
MX2019001920A
(es)
|
2016-08-19 |
2019-07-01 |
Curevac Ag |
Arn la terapia contra el cancer.
|
|
MX2018009853A
(es)
|
2016-09-02 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos de direccion.
|
|
BR112019004935A2
(pt)
|
2016-09-13 |
2019-06-04 |
Allergan, Inc. |
composições de toxina clostridial não proteíca estabilizada
|
|
US11471533B2
(en)
|
2016-09-27 |
2022-10-18 |
Kyowa Kirin Co., Ltd. |
Compound usable as cationic lipid
|
|
TW201813632A
(zh)
*
|
2016-09-28 |
2018-04-16 |
日商協和醱酵麒麟有限公司 |
含有核酸之脂質奈米粒子
|
|
EP3522898A4
(en)
|
2016-10-06 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS
|
|
EP3527570A4
(en)
|
2016-10-14 |
2020-04-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
ES3063077T3
(en)
|
2016-10-26 |
2026-04-15 |
Acuitas Therapeutics Inc |
Lipid nanoparticle formulations
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3538515B1
(en)
*
|
2016-11-08 |
2022-07-20 |
Ramot at Tel-Aviv University Ltd. |
Cationic lipids for nucleic acid delivery and preparation thereof
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
EP3551230A1
(en)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
CN110582301A
(zh)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和蛋白质有效负载递送的方法和组合物
|
|
EP3558356A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Mers coronavirus vaccine
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
EA201991747A1
(ru)
|
2017-02-27 |
2020-06-04 |
Транслейт Био, Инк. |
НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
SMT202300097T1
(it)
|
2017-03-15 |
2023-05-12 |
Modernatx Inc |
Composto e composizioni per il rilascio intracellulare di agenti terapeutici
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US11969506B2
(en)
|
2017-03-15 |
2024-04-30 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
WO2019012336A2
(en)
|
2017-03-17 |
2019-01-17 |
Newcastle University |
ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
AU2018240515B2
(en)
|
2017-03-24 |
2024-07-25 |
CureVac SE |
Nucleic acids encoding CRISPR-associated proteins and uses thereof
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
US11433026B2
(en)
*
|
2017-03-31 |
2022-09-06 |
University Of Rhode Island Board Of Trustees |
Nanoparticle-induced fusogenicity between liposome and endosome membranes for targeted delivery through endosomal escape
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
IL269927B2
(en)
|
2017-04-18 |
2025-04-01 |
Alnylam Pharmaceuticals Inc |
Methods of treating patients with hepatitis B virus infection
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
MX2019013752A
(es)
|
2017-05-16 |
2020-07-20 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
|
|
ES3039647T3
(en)
|
2017-05-31 |
2025-10-23 |
Arcturus Therapeutics Inc |
Synthesis and structure of high potency rna therapeutics
|
|
EP3630200A4
(en)
|
2017-05-31 |
2021-02-24 |
Arcturus Therapeutics, Inc. |
THERAPEUTICS FOR PHENYLKETONURIA
|
|
WO2018222926A1
(en)
|
2017-05-31 |
2018-12-06 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for glycogen storage disease type iii
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
RU2020103379A
(ru)
|
2017-07-04 |
2021-08-04 |
Куревак Аг |
Новые молекулы нуклеиновых кислот
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
EP3662913A4
(en)
|
2017-08-04 |
2021-06-30 |
Kyowa Kirin Co., Ltd. |
Nucleic-acid-containing lipid nanoparticles
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP3668834B1
(en)
|
2017-08-17 |
2024-10-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
KR20250046363A
(ko)
|
2017-09-19 |
2025-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
|
CN111630173A
(zh)
|
2017-10-19 |
2020-09-04 |
库瑞瓦格股份公司 |
新型人工核酸分子
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
EP3707271A1
(en)
|
2017-11-08 |
2020-09-16 |
CureVac AG |
Rna sequence adaptation
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
EP3727428A1
(en)
|
2017-12-20 |
2020-10-28 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
CN111712468A
(zh)
|
2017-12-22 |
2020-09-25 |
北卡罗莱纳州立大学 |
聚合物荧光团、包含其的组合物及制备和使用其的方法
|
|
MX2020006843A
(es)
|
2017-12-27 |
2020-09-03 |
Takeda Pharmaceuticals Co |
Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
|
|
BR112020014425A2
(pt)
|
2018-01-15 |
2020-12-29 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de dnm2
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
CN108310455B
(zh)
*
|
2018-03-20 |
2021-07-30 |
嘉兴尔云信息科技有限公司 |
纳米羟基磷灰石、pgs-m复合骨修复材料及其制备方法
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
KR102890791B1
(ko)
|
2018-04-09 |
2025-11-24 |
체크메이트 파마슈티칼스, 인크. |
바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
|
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｆｘｉの発現を低下させるための化合物及び方法
|
|
PL3805198T3
(pl)
|
2018-06-08 |
2024-02-12 |
Fujifilm Corporation |
Związek, jego sól i cząstki lipidowe
|
|
CN120393053A
(zh)
|
2018-06-18 |
2025-08-01 |
全国儿童医院研究所 |
用于治疗肌营养不良的肌肉特异性微小肌营养不良蛋白的腺相关病毒载体递送
|
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
US20210292768A1
(en)
|
2018-08-08 |
2021-09-23 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
CA3108544A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
TWI856973B
(zh)
|
2018-09-19 |
2024-10-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CN113271926A
(zh)
|
2018-09-20 |
2021-08-17 |
摩登纳特斯有限公司 |
脂质纳米颗粒的制备及其施用方法
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
CN112789031B
(zh)
|
2018-09-28 |
2023-03-24 |
胡桃钳医疗公司 |
用于核酸递送的包含脂化的阳离子肽化合物的脂质纳米颗粒制剂
|
|
ES3046484T3
(en)
*
|
2018-10-01 |
2025-12-02 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
CN113166783B
(zh)
|
2018-10-09 |
2024-10-11 |
不列颠哥伦比亚大学 |
包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
|
|
JP7543259B2
(ja)
*
|
2018-10-18 |
2024-09-02 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
WO2020080475A1
(ja)
|
2018-10-18 |
2020-04-23 |
武田薬品工業株式会社 |
Ｔ細胞の活性化／増殖方法
|
|
WO2020106903A1
(en)
*
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
MX2021005969A
(es)
|
2018-11-21 |
2021-09-14 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
|
|
JP7445657B2
(ja)
|
2018-12-06 |
2024-03-07 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
CA3118034A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
EP3899024A4
(en)
|
2018-12-21 |
2023-05-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of hsd17b13 expression
|
|
MY202837A
(en)
|
2019-01-11 |
2024-05-24 |
Acuitas Therapeutics Inc |
Lipids for lipid nanoparticle delivery of active agents
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
CN112010995A
(zh)
*
|
2019-05-30 |
2020-12-01 |
株式会社大赛璐 |
壳聚糖衍生物及光学异构体用分离剂
|
|
CN110041223B
(zh)
*
|
2019-06-03 |
2021-10-22 |
西北师范大学 |
以肼类化合物为原料氧化合成偶氮类化合物的方法
|
|
WO2020246581A1
(ja)
|
2019-06-07 |
2020-12-10 |
富士フイルム株式会社 |
脂質組成物
|
|
US20220313813A1
(en)
|
2019-06-18 |
2022-10-06 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
US12503432B2
(en)
|
2019-06-20 |
2025-12-23 |
Global Life Sciences Solutions Canada Ulc |
Ionizable lipids for nucleic acid delivery
|
|
JP7420841B2
(ja)
*
|
2019-06-29 |
2024-01-23 |
プレシジョン ナノシステムズ ユーエルシー |
核酸送達のためのイオン化可能な脂質
|
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
|
EP4013880A1
(en)
|
2019-08-14 |
2022-06-22 |
CureVac AG |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
US20230097090A1
(en)
|
2019-08-14 |
2023-03-30 |
Acuitas Therapeutics, Inc. |
Improved lipid nanoparticles for delivery of nucleic acids
|
|
BR112022004936A2
(pt)
|
2019-09-19 |
2022-06-14 |
Modernatx Inc |
Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
EP4045062A1
(en)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulators of pnpla3 expression
|
|
CN119499394A
(zh)
|
2019-11-01 |
2025-02-25 |
阿尔尼拉姆医药品有限公司 |
亨廷顿（HTT）iRNA药剂组合物及其使用方法
|
|
EP4059505B1
(en)
|
2019-11-15 |
2024-02-21 |
FUJIFILM Corporation |
Lipid composition
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
EP4073251A1
(en)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
KR20220121246A
(ko)
|
2019-12-20 |
2022-08-31 |
큐어백 아게 |
핵산 전달용 신규한 지질 나노입자
|
|
MX2022009460A
(es)
|
2020-02-04 |
2022-12-16 |
Curevac Ag |
Vacuna contra el coronavirus.
|
|
KR20220143106A
(ko)
|
2020-02-18 |
2022-10-24 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
|
|
CR20220485A
(es)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
JP7832114B2
(ja)
|
2020-03-03 |
2026-03-17 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症の治療のための組成物及び方法
|
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
WO2021183563A1
(en)
|
2020-03-09 |
2021-09-16 |
Arcturus Therapeutics, Inc. |
Coronavirus vaccine compositions and methods
|
|
JP7709981B2
(ja)
*
|
2020-03-17 |
2025-07-17 |
ジェネヴァント サイエンシズ ゲーエムベーハー |
肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
|
|
MX2022011805A
(es)
|
2020-03-24 |
2023-01-11 |
Generation Bio Co |
Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
|
|
AU2021244559A1
(en)
|
2020-03-24 |
2022-11-17 |
Generation Bio Co. |
Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics
|
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
WO2021198157A1
(en)
|
2020-03-30 |
2021-10-07 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2021202902A1
(en)
|
2020-04-01 |
2021-10-07 |
Alnylam Pharmaceuticals, Inc. |
ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
AU2021260934A1
(en)
|
2020-04-21 |
2022-11-24 |
Flagship Pioneering, Inc. |
Bifunctional molecules and methods of using thereof
|
|
KR20230018377A
(ko)
|
2020-04-27 |
2023-02-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
|
|
US12070509B2
(en)
|
2020-05-01 |
2024-08-27 |
Arcturus Therapeutics, Inc. |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
CN111575310B
(zh)
*
|
2020-05-14 |
2022-12-13 |
江南大学 |
表达小窝蛋白的重组酿酒酵母及其应用
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
CA3179420A1
(en)
|
2020-05-20 |
2021-11-25 |
Avak Kahvejian |
Coronavirus antigen compositions and their uses
|
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
CA3180101A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
|
MX2022015132A
(es)
|
2020-05-29 |
2023-03-08 |
CureVac SE |
Vacunas combinadas a base de acidos nucleicos.
|
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
EP4164668A1
(en)
|
2020-06-15 |
2023-04-19 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
|
CN115916743B
(zh)
*
|
2020-06-16 |
2025-12-23 |
法国特种经营公司 |
用作表面活性剂的新型铵化合物
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
CN111714468B
(zh)
*
|
2020-06-30 |
2022-02-11 |
郑州大学 |
一种siRNA递送系统复合物及其制备方法和用途
|
|
CN116367854A
(zh)
|
2020-07-08 |
2023-06-30 |
杨森科学爱尔兰无限公司 |
针对hbv的rna复制子疫苗
|
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
CN116234917A
(zh)
|
2020-07-27 |
2023-06-06 |
安杰瑞姆生物科学公司 |
Dna分子组合物及其制备方法和使用方法
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
US12178921B2
(en)
|
2020-08-14 |
2024-12-31 |
Arcturus Therapeutics, Inc. |
Method of lyophilizing lipid nanoparticles
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3170743A1
(en)
|
2020-08-31 |
2022-03-03 |
Susanne RAUCH |
Multivalent nucleic acid based coronavirus vaccines
|
|
MX2023002439A
(es)
|
2020-09-03 |
2023-05-09 |
Flagship Pioneering Innovations Vi Llc |
Composiciones immunogénicas y usos de las mismas.
|
|
WO2022056413A1
(en)
|
2020-09-13 |
2022-03-17 |
Arcturus Therapeutics, Inc. |
Lipid nanoparticles encapsulation of large rna
|
|
JP7518909B2
(ja)
|
2020-09-14 |
2024-07-18 |
富士フイルム株式会社 |
脂質組成物
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
US20230331670A1
(en)
*
|
2020-09-17 |
2023-10-19 |
Enzychem Lifesciences Corporation |
Glycerol compounds and methods of use
|
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｇタンパク質共役受容体７５（ＧＰＲ７５）ｉＲＮＡ組成物およびその使用方法
|
|
EP4225322A4
(en)
*
|
2020-10-09 |
2024-12-11 |
Adarx Pharmaceuticals, Inc. |
N-acetylgalactosamine(galnac)-derived compounds and oligonucleotides
|
|
JP2023546175A
(ja)
|
2020-10-14 |
2023-11-01 |
ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド |
脂質ナノ粒子製造の方法及びそれに由来する組成物
|
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
EP4136092B1
(en)
|
2020-11-18 |
2024-07-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
IL303195A
(en)
|
2020-11-25 |
2023-07-01 |
Akagera Medicines Inc |
Lipid nanoparticles for delivery of nucleic acids and related methods of use
|
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
WO2022140404A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Cornell University |
Zwitterionic lipid nanoparticle compositions, and methods of use
|
|
IL303886A
(en)
|
2020-12-23 |
2023-08-01 |
Flagship Pioneering Inc |
Compositions of modified trems and uses thereof
|
|
US20240316090A1
(en)
|
2020-12-28 |
2024-09-26 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
JP2024504614A
(ja)
*
|
2021-01-14 |
2024-02-01 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡがコードする抗体を送達する方法および組成物
|
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US20240180954A1
(en)
|
2021-02-04 |
2024-06-06 |
Shionogi & Co., Ltd. |
Cationic lipid
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
US20240140960A1
(en)
*
|
2021-02-12 |
2024-05-02 |
Ohio State Innovation Foundation |
Sugar derived lipid nanomaterials and uses thereof
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
US20240181037A1
(en)
|
2021-03-26 |
2024-06-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
WO2022212231A2
(en)
|
2021-03-29 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
EP4312988A2
(en)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
EP4321524B1
(en)
*
|
2021-04-09 |
2025-12-10 |
Sogo Pharmaceutical Co., Ltd. |
Lipid and composition
|
|
AU2022260111A1
(en)
|
2021-04-20 |
2023-11-30 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
CN117881786A
(zh)
|
2021-04-27 |
2024-04-12 |
世代生物公司 |
表达治疗性抗体的非病毒dna载体及其用途
|
|
KR20230162043A
(ko)
|
2021-04-28 |
2023-11-28 |
후지필름 가부시키가이샤 |
화합물 또는 그 염, 지질 입자 및 의약 조성물
|
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
EP4342993A4
(en)
*
|
2021-05-19 |
2025-05-28 |
Daiichi Sankyo Company, Limited |
Hpv infectious disease vaccine
|
|
EP4347554A4
(en)
*
|
2021-05-28 |
2025-10-22 |
Nanovation Therapeutics Inc |
MC3 TYPE LIPIDS AND THEIR USE IN THE PREPARATION OF LIPID NANOPARTICLES
|
|
US20240287015A1
(en)
*
|
2021-05-28 |
2024-08-29 |
Nanovation Therapeutics Inc. |
Method for Producing an Ionizable Lipid
|
|
CN117561334A
(zh)
|
2021-06-04 |
2024-02-13 |
阿尔尼拉姆医药品有限公司 |
人染色体9开放阅读框72（C9ORF72）iRNA药剂组合物和其使用方法
|
|
KR20220167770A
(ko)
|
2021-06-11 |
2022-12-21 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
WO2023034837A2
(en)
|
2021-08-31 |
2023-03-09 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
MX2024002726A
(es)
|
2021-09-03 |
2024-03-20 |
CureVac SE |
Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
|
|
WO2023031392A2
(en)
|
2021-09-03 |
2023-03-09 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
CN115772089B
(zh)
*
|
2021-09-07 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
ES2994006T3
(en)
|
2021-09-17 |
2025-01-16 |
Flagship Pioneering Innovations Vi Llc |
Compositions and methods for producing circular polyribonucleotides
|
|
KR20240067943A
(ko)
|
2021-09-24 |
2024-05-17 |
알닐람 파마슈티칼스 인코포레이티드 |
미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
|
|
MX2024004011A
(es)
|
2021-10-01 |
2024-07-01 |
Adarx Pharmaceuticals Inc |
Composiciones moduladoras de precalicreína y métodos de uso de estas.
|
|
JP2024538144A
(ja)
|
2021-10-18 |
2024-10-18 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
ポリリボヌクレオチドを精製するための組成物及び方法
|
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
EP4430024A1
(en)
|
2021-11-08 |
2024-09-18 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
KR102772764B1
(ko)
|
2021-11-10 |
2025-02-27 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
|
WO2023091490A1
(en)
|
2021-11-16 |
2023-05-25 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
WO2023091787A1
(en)
|
2021-11-22 |
2023-05-25 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
MX2024006440A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones inmunogenicas y sus usos.
|
|
EP4436984A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
AU2022397292A1
(en)
|
2021-11-24 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
|
US20250049714A1
(en)
*
|
2021-12-09 |
2025-02-13 |
Massachusetts Institute Of Technology |
Synthesis of ester, carbonate, and carbamate-derived novel biodegradable ionizable lipids from methyl ricinoleate or methyl 12-hydroxystearate and its applications
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP2024546855A
(ja)
|
2021-12-17 |
2024-12-26 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
変性条件下での環状ｒｎａの濃縮方法
|
|
KR20240117149A
(ko)
|
2021-12-22 |
2024-07-31 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
MX2024007870A
(es)
|
2021-12-23 |
2024-08-15 |
Flagship Pioneering Innovations Vi Llc |
Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
CA3242744A1
(en)
|
2022-01-27 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for the administration of herpes simplex virus antigens and associated methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4691500A3
(en)
|
2022-03-15 |
2026-04-01 |
FUJIFILM Corporation |
Lipid composition
|
|
EP4499607A1
(en)
|
2022-03-25 |
2025-02-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
CN114933569B
(zh)
*
|
2022-04-07 |
2024-07-23 |
澳门科技大学 |
鞘脂类化合物、含有鞘脂类化合物的脂质体和应用
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
WO2023198828A1
(en)
|
2022-04-13 |
2023-10-19 |
Universitat Autònoma De Barcelona |
Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
|
|
US20250295687A1
(en)
|
2022-05-09 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
JP2025516638A
(ja)
|
2022-05-13 |
2025-05-30 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
二本鎖ｄｎａ組成物及び関連する方法
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
|
CN117203186A
(zh)
*
|
2022-05-13 |
2023-12-08 |
南方科技大学 |
一种含有二硫键的脂质化合物及其组合物
|
|
EP4641202A3
(en)
|
2022-05-25 |
2026-01-21 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulation of immune responses
|
|
CA3253328A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Modulation Methods of Genetic Drivers
|
|
EP4531819A2
(en)
|
2022-05-25 |
2025-04-09 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
KR20250021330A
(ko)
|
2022-05-25 |
2025-02-12 |
비온테크 에스이 |
원숭이두창 항원 전달을 위한 rna 조성물 및 관련 방법
|
|
JP2025517969A
(ja)
|
2022-05-25 |
2025-06-12 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
腫瘍抑制因子及び癌遺伝子の調節のための組成物及び方法
|
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
US20250319115A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Cytokines
|
|
US20250320254A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Circulating Factors
|
|
US20250375534A1
(en)
|
2022-05-30 |
2025-12-11 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
|
EP4536197A1
(en)
|
2022-06-07 |
2025-04-16 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
EP4562154A2
(en)
|
2022-07-29 |
2025-06-04 |
Massachusetts Institute of Technology |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPalpha) GENE
|
|
JP2025525778A
(ja)
|
2022-08-01 |
2025-08-07 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
免疫調節タンパク質及び関連方法
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
AU2023334610A1
(en)
|
2022-08-31 |
2025-03-13 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CN120152962A
(zh)
|
2022-09-06 |
2025-06-13 |
国立大学法人九州大学 |
脂质纳米粒子
|
|
JP2025533541A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
肝病期抗原の送達のための組成物及び関連方法
|
|
KR20250110209A
(ko)
|
2022-09-23 |
2025-07-18 |
엔크로마 바이오, 인크. |
Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
EP4590331A1
(en)
|
2022-09-23 |
2025-07-30 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
CN119947747A
(zh)
|
2022-09-26 |
2025-05-06 |
葛兰素史克生物有限公司 |
流感病毒疫苗
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
CN120129702A
(zh)
|
2022-10-06 |
2025-06-10 |
生物技术公司 |
靶向密蛋白-18.2的rna组合物
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
AU2023372397A1
(en)
|
2022-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
EP4615465A1
(en)
|
2022-11-08 |
2025-09-17 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for producing circular polyribonucleotides
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
CN120390656A
(zh)
|
2022-11-08 |
2025-07-29 |
欧纳医疗公司 |
环状rna组合物
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
KR20250114116A
(ko)
|
2022-12-01 |
2025-07-28 |
제너레이션 바이오 컴퍼니 |
세포 표적화를 위한 스텔스 지질 나노입자 조성물
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
KR20250131271A
(ko)
|
2022-12-01 |
2025-09-02 |
제너레이션 바이오 컴퍼니 |
신규한 폴리글리세롤-접합된 지질 및 이를 포함하는 지질 나노입자 조성물
|
|
JP2025540076A
(ja)
|
2022-12-01 |
2025-12-11 |
ジェネレーション バイオ カンパニー |
核酸、イオン化可能な脂質、ステロール、脂質アンカーポリマー、及びヘルパー脂質を含む脂質ナノ粒子、それらの使用
|
|
EP4630561A1
(en)
|
2022-12-09 |
2025-10-15 |
Takeda Pharmaceutical Company Limited |
Modified immunomodulators
|
|
EP4631527A1
(en)
|
2022-12-09 |
2025-10-15 |
Seoul National University R&DB Foundation |
Nanoparticle comprising peptide-based conjugate for delivering mrna into b cell and t cell and uses thereof
|
|
WO2024123139A1
(ko)
|
2022-12-09 |
2024-06-13 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
JP2025534494A
(ja)
*
|
2022-12-23 |
2025-10-15 |
グリーン・クロス・コーポレイション |
イオン化可能な脂質及びその使用
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151583A2
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
EP4656628A1
(en)
|
2023-01-27 |
2025-12-03 |
FUJIFILM Corporation |
Compound or salt thereof, lipid composition, pharmaceutical composition, and delivery carrier
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
IL322378A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA compositions containing modified cytosine
|
|
JP2026507513A
(ja)
|
2023-02-17 |
2026-03-04 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
修飾されたウラシルを含むｄｎａ組成物
|
|
KR20250153298A
(ko)
|
2023-03-08 |
2025-10-24 |
큐어백 에스이 |
핵산 전달을 위한 신규의 지질 나노입자 제형
|
|
EP4680276A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
WO2024192420A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
AU2024254671A1
(en)
|
2023-03-30 |
2025-10-02 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
CN121358499A
(zh)
|
2023-03-30 |
2026-01-16 |
Ose免疫疗法 |
靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途
|
|
WO2024210160A1
(en)
|
2023-04-07 |
2024-10-10 |
Takeda Pharmaceutical Company Limited |
Conjugation complex
|
|
WO2024216191A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024220930A2
(en)
|
2023-04-20 |
2024-10-24 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
EP4701658A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
CN121399470A
(zh)
|
2023-05-03 |
2026-01-23 |
马尼福尔德生物技术有限公司 |
用于高通量蛋白质递送、筛选和检测的方法和组合物
|
|
WO2024228150A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
CN121398851A
(zh)
|
2023-05-12 |
2026-01-23 |
阿达尔克斯制药有限公司 |
Nmda配体缀合的化合物及其用途
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
IL324634A
(en)
|
2023-05-15 |
2026-01-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
|
WO2024236361A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for delivery of nucleic acids to cells
|
|
AU2024272171A1
(en)
*
|
2023-05-18 |
2025-12-04 |
Vycellix, Inc. |
Plasma membrane embedded system for spaciotemporal controlled payload delivery of biologics
|
|
KR20260015278A
(ko)
*
|
2023-05-25 |
2026-02-02 |
브리스톨-마이어스 스큅 컴퍼니 |
이온화가능한 지질
|
|
IL324720A
(en)
|
2023-05-26 |
2026-01-01 |
Adarx Pharmaceuticals Inc |
SOD1 modulators and methods of using them
|
|
EP4725938A1
(en)
*
|
2023-06-07 |
2026-04-15 |
InnoVec Biotherapeutics |
Ionizable lipid compound, lipid carrier comprising same and use thereof
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
CN121712891A
(zh)
|
2023-06-20 |
2026-03-20 |
阿达尔克斯制药有限公司 |
Lrrk2调节组合物及其使用方法
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
TW202517669A
(zh)
|
2023-07-05 |
2025-05-01 |
日商武田藥品工業股份有限公司 |
用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
TW202515531A
(zh)
|
2023-07-07 |
2025-04-16 |
美商輝瑞股份有限公司 |
兩親性ｔｌｒ７／８佐劑及其用途
|
|
CN121816193A
(zh)
|
2023-07-21 |
2026-04-07 |
生物技术欧洲股份公司 |
用于递送疟原虫抗原的组合物及相关方法
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
IL325898A
(en)
|
2023-07-24 |
2026-03-01 |
BioNTech SE |
Compositions for administering Plasmodium antigens and related methods
|
|
AU2024299627A1
(en)
|
2023-07-25 |
2026-01-22 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
CN121620589A
(zh)
|
2023-08-01 |
2026-03-06 |
法国居里学院 |
包含编码环gmp-amp合酶的核酸序列的纳米粒子
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
IL326176A
(en)
|
2023-08-01 |
2026-03-01 |
BioNTech SE |
Ionizable Thiolipids and Their Uses
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
CN121772938A
(zh)
|
2023-08-03 |
2026-03-31 |
百欧恩泰欧洲股份公司 |
用于递送单纯疱疹病毒抗原的药物组合物及相关方法
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
CN121752588A
(zh)
|
2023-08-29 |
2026-03-27 |
上海环码生物医药有限公司 |
编码vegf多肽的环状rna、制剂和使用方法
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
CN121844046A
(zh)
|
2023-09-11 |
2026-04-10 |
C·米库尔卡 |
用于递送肠促胰岛素剂的rna组合物
|
|
AU2024344058A1
(en)
|
2023-09-18 |
2026-04-02 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025064591A1
(en)
*
|
2023-09-19 |
2025-03-27 |
The Regents Of The University Of California |
In vivo gene editing of tau locus via liponanoparticle delivery
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025133115A1
(en)
|
2023-12-21 |
2025-06-26 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising il-35
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025157978A1
(en)
*
|
2024-01-26 |
2025-07-31 |
Merck Patent Gmbh |
Ionizable lipids for use in lipid nanoparticles
|
|
WO2025166323A2
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting lipoprotein (a) expression
|
|
WO2025180874A1
(en)
*
|
2024-02-27 |
2025-09-04 |
Basf Se |
Substituted 1,3-dioxolane sulfates and their use
|
|
TW202543583A
(zh)
|
2024-03-01 |
2025-11-16 |
加拿大商阿奎特斯醫療公司 |
用於將治療劑包覆於脂質奈米顆粒中之材料及方法
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
WO2026035680A1
(en)
|
2024-08-06 |
2026-02-12 |
Kernal Biologics, Inc. |
Compositions and methods for delivery of agents
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|
|
WO2026068864A1
(en)
|
2024-09-30 |
2026-04-02 |
BioNTech SE |
Engineered ch1 and cl domains for the prevention of chain mispairing
|